

**Connect Biopharma Holdings Limited**

Science and Technology Park  
East R&D Building, 3rd Floor  
6 Beijing West Road, Taicang  
Jiangsu Province, China 215400

July 1, 2022

**VIA EDGAR**

Ms. Jane Park  
Office of Life Sciences  
Division of Corporation Finance  
U.S. Securities and Exchange Commission  
100 F Street N.E.  
Washington, D.C. 20549

**Re: Connect Biopharma Holdings Limited  
Registration Statement on Form F-3  
File No. 333-264340**

Dear Ms. Park:

Pursuant to Rule 461 of Regulation C of the General Rules and Regulations under the Securities Act of 1933, as amended, the undersigned, on behalf of Connect Biopharma Holdings Limited (the "**Company**"), respectfully requests that the effective date of the Registration Statement on Form F-3 referred to above be accelerated so that it will become effective at 4:00 P.M. Eastern Time on July 6, 2022, or as soon as practicable thereafter.

Please contact Michael E. Sullivan of Latham & Watkins LLP, counsel to the Company, at (858) 523-3959, to provide notice of effectiveness, or if you have any questions or require additional information regarding this matter. Thank you for your assistance and cooperation in this matter.

Very truly yours,

CONNECT BIOPHARMA HOLDINGS LIMITED

By: /s/ Zheng Wei, Ph.D.

Zheng Wei, Ph.D.  
Chief Executive Officer

cc: Jason Drory, *Securities Exchange Commission*  
Jiang Bian, Esq., *Connect Biopharma Holdings Limited*  
Michael E. Sullivan, *Latham & Watkins LLP*  
Cheung Ying (Cathy) Yeung, Esq., *Latham & Watkins LLP*  
Alan F. Denenberg, *Davis Polk & Wardwell LLP*  
Emily Roberts, *Davis Polk & Wardwell LLP*  
Donald K. Lang, *Davis Polk & Wardwell LLP*